Emily Z Keung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6598853/publications.pdf Version: 2024-02-01



EMILY 7 KELING

#	Article	IF	CITATIONS
1	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
2	B cells are associated with survival and immunotherapy response in sarcoma. Nature, 2020, 577, 556-560.	27.8	1,158
3	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Review of Anticancer Therapy, 2018, 18, 775-784.	2.4	268
4	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the United States of America, 2019, 116, 22246-22251.	7.1	142
5	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clinical Cancer Research, 2020, 26, 1258-1266.	7.0	115
6	Treatment at lowâ€volume hospitals is associated with reduced shortâ€ŧerm and longâ€ŧerm outcomes for patients with retroperitoneal sarcoma. Cancer, 2018, 124, 4495-4503.	4.1	100
7	Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery. Journal of the American College of Surgeons, 2014, 218, 206-217.	0.5	99
8	Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. European Journal of Surgical Oncology, 2018, 44, 170-177.	1.0	82
9	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Reports, 2017, 19, 875-889.	6.4	78
10	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer, 2018, 18, 913.	2.6	69
11	Immunocompromised Status in Patients With Necrotizing Soft-Tissue Infection. JAMA Surgery, 2013, 148, 419.	4.3	68
12	Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Network Open, 2021, 4, e210945.	5.9	66
13	Dual Roles of RNF2 in Melanoma Progression. Cancer Discovery, 2015, 5, 1314-1327.	9.4	57
14	In-Hospital and Long-Term Outcomes after Percutaneous Endoscopic Gastrostomy in Patients with Malignancy. Journal of the American College of Surgeons, 2012, 215, 777-786.	0.5	53
15	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncolmmunology, 2018, 7, e1385689.	4.6	46
16	Concise Review: Genetically Engineered Stem Cell Therapy Targeting Angiogenesis and Tumor Stroma in Gastrointestinal Malignancy. Stem Cells, 2013, 31, 227-235.	3.2	45
17	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Annals of Surgical Oncology, 2018, 25, 1814-1827.	1.5	45
18	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Reports, 2020, 33, 108293.	6.4	39

Emily Z Keung

#	Article	IF	CITATIONS
19	Management of Gastrointestinal Stromal Tumors. Surgical Clinics of North America, 2017, 97, 437-452.	1.5	35
20	The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors. Current Treatment Options in Oncology, 2016, 17, 8.	3.0	27
21	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. Journal of the National Cancer Institute, 2020, 112, 875-885.	6.3	20
22	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, 369-386.	1.5	19
23	Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. Surgical Oncology, 2020, 34, 182-185.	1.6	19
24	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathologica, 2021, 142, 565-590.	7.7	12
25	Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Annals of Surgical Oncology, 2022, 29, 4376-4385.	1.5	12
26	Surgical Management of Metastatic Disease. Surgical Clinics of North America, 2016, 96, 1175-1192.	1.5	10
27	Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. American Journal of Surgery, 2020, 220, 140-146.	1.8	9
28	<scp>Realâ€world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. International Journal of Cancer, 2022, 150, 2012-2024.	5.1	8
29	Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. Journal of Investigative Dermatology, 2022, 142, 2046-2049.e3.	0.7	8
30	Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. Annals of Surgical Oncology, 2022, 29, 7092-7100.	1.5	8
31	The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center. Journal of Surgical Oncology, 2018, 117, 1799-1805.	1.7	7
32	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVIDâ€19 pandemic: A guide for surgical oncologists. Journal of Surgical Oncology, 2021, 123, 12-23.	1.7	7
33	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489.	1.5	7
34	Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
35	Disseminated Coccidioidomycosis Following COVID-19 Mimicking Metastatic Thoracic Relapse of Well-Differentiated Liposarcoma: A Case Report. Frontiers in Medicine, 2021, 8, 715939.	2.6	6
36	The degree of sclerosis is associated with prognosis in wellâ€differentiated liposarcoma of the retroperitoneum. Journal of Surgical Oncology, 2019, 120, 382-388.	1.7	5

Emily Z Keung

#	Article	IF	CITATIONS
37	Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Practical Radiation Oncology, 2022, 12, 437-445.	2.1	5
38	Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. Annals of Surgical Oncology, 2021, 28, 570-575.	1.5	4
39	Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!. Cancer Discovery, 2018, 8, 914-917.	9.4	3
40	H3K9me3-mediated repression of KLF6: Discovering a novel tumor suppressor in liposarcoma using a systematic epigenomic approach. Molecular and Cellular Oncology, 2016, 3, e1093691.	0.7	2
41	Accurate and Reproducible Diagnosis of Canine Soft Tissue Sarcoma Using Mass Spectrometry: A Step in the Right Direction. Cancer Cell, 2018, 34, 697-699.	16.8	2
42	Management of Skin Sarcomas. Surgical Oncology Clinics of North America, 2022, 31, 511-525.	1.5	2
43	Utilization and evolving prescribing practice of opioid and nonâ€opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. Journal of Surgical Oncology, 2022, 125, 719-729.	1.7	1
44	ASO Author Reflections: Lymph Node Disease in Soft Tissue Sarcoma: A Problematic Clinical Dilemma. Annals of Surgical Oncology, 2022, , 1.	1.5	1
45	Window-of-Opportunity Trials: The Road Forward in Soft Tissue Sarcoma and Beyond. Annals of Surgical Oncology, 2019, 26, 1188-1189.	1.5	0
46	ASO Author Reflections: Surveillance After Resection of Retroperitoneal Well-Differentiated Liposarcoma: A Balancing Act Between Earlier Recurrence Detection, Patient Anxiety, and Health Care Resource Expenditure. Annals of Surgical Oncology, 2020, 27, 748-749.	1.5	0
47	ASO Visual Abstract: Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients, Annals of Survical Oncology, 2022, 1	1.5	0